Skip to main content
N

NEXSEN

The startup develops a rapid point-of-care diagnostic test for Group B Streptococcus (GBS) using a streamlined assay method that provides instant results for infections in the digestive and lower reproductive tracts. This test enables healthcare providers to quickly identify GBS, reducing transmission risks and improving patient outcomes.

Melbourne, AustraliaFounded 202181K+ followers
Updated 3 months ago

Funding

$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Features

  • The startup develops a rapid point-of-care diagnostic test for Group B Streptococcus (GBS) using a streamlined assay method that provides instant results for infections in the digestive and lower reproductive tracts. This test enables healthcare providers to quickly identify GBS, reducing transmission risks and improving patient outcomes.
This profile is AI-generated and may contain inaccuracies.